Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)

التفاصيل البيبلوغرافية
العنوان: Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)
المؤلفون: Al-Ola Abdallah, Andrew J Cowan, Xavier Leleu, Cyrille Touzeau, Brea Lipe, Eva Medvedova, Caitlin Costello, Jens Hillengass, P. Leif Bergsagel, Raya Mawad, Henning Schade, Daniel Morillo Giles, Albert Oriol, Yifah Yaron, Patrick P Ng, Sumit Madan
المصدر: Blood. 140:7284-7285
بيانات النشر: American Society of Hematology, 2022.
سنة النشر: 2022
مصطلحات موضوعية: Immunology, Cell Biology, Hematology, Biochemistry
تدمد: 1528-0020
0006-4971
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::1c579ad0e7449725f156f6b1170bebdf
https://doi.org/10.1182/blood-2022-159665
رقم الأكسشن: edsair.doi...........1c579ad0e7449725f156f6b1170bebdf
قاعدة البيانات: OpenAIRE